Cargando…
P905: IXAZOMIB-THALIDOMIDE-DEXAMETHASONE INDUCTION FOLLOWED BY IXAZOMIB OR PLACEBO MAINTENANCE IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS; LONG-TERM RESULTS OF HOVON-126/NMSG 21.13
Autores principales: | Groen, K., Seefat, M. R., van der Holt, B., Schjesvold, F. H., Stege, C. A., Levin, M.-D., Hansson, M., Leys, R. B., Regelink, J., Waage, A., Szatkowski, D., Axelsson, P., Do, T. H., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C., Mellqvist, U.-H., van de Donk, N. W., Sonneveld, P., Klostergaard, A., Vangsted, A. J., Abdilgaard, N., Zweegman, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429083/ http://dx.doi.org/10.1097/01.HS9.0000846492.51234.76 |
Ejemplares similares
-
Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
por: Groen, Kazimierz, et al.
Publicado: (2023) -
Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
por: Zweegman, Sonja, et al.
Publicado: (2020) -
P906: IXAZOMIB, DARATUMUMAB AND LOW DOSE DEXAMETHASONE IN FRAIL PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): RESULTS OF THE MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2022) -
P13 IXAZOMIB, DARATUMUMAB AND LOW-DOSE DEXAMETHASONE IN INTERMEDIATE-FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY
por: Groen, K., et al.
Publicado: (2023) -
Sweet Syndrome Associated with Ixazomib
por: Yavaşoğlu, İrfan, et al.
Publicado: (2021)